ECSEL JOINT UNDERTAKING COORDINATOR’S DAY 2019
AGENDA

9:00- 9:30    Registration and welcome coffee
9:30- 9:40    Welcome and introduction
9:40- 10:00   ECSEL in a nutshell
10:00- 11:00  Reporting and Payment including Reviews
11:00- 11:30  coffee break
11:30- 12:00  Audits: different types of audits, CFEs, how do we process audits, etc.
12:00- 12:30  Do’s and Don’t’s in Payments, Sygma Compas
12:30- 12:35  Meet the staff
12:35- 13:30  Lunch
13:30- 14:00  Amendments and updates of the GA
14:00- 14:15  Communication -
14:15- 14:45  Dissemination, exploitation (dissemination and exploitation, open access, etc.)
14:45- 15:00  Evaluations
15:00- 16:00  Open discussion, future of ECSEL, free discussion with coffee
16:00           End with possibility to meet your PO after appointment
ECSEL IN A NUTSHELL

Governance
ECSEL A UNIQUE GOVERNANCE MODEL

AUTONOMOUS UNION BODY WITH LEGAL PERSONALITY
TRIPARTITE, PUBLIC PRIVATE PARTNERSHIP, JOINT UNDERTAKING

Governing Board
ECSEL Members
(Public Authorities, Private Members)

Executive Director
Programme Office

Public Authorities Board
European Commission,
ECSEL Participating States

Private Members Board
AENEAS, ARTEMIS-IA, EPoSS

ECSEL-Office:
Staff (incl Mgmt): 12 Operational, 17 Admin, IT & Finance,
4 Communication, 1 Executive director

EPS = signed an administrative agreement
- 23 Member States
- CH, NO, IL and TR are also EPS
- Luxembourg is soon joining as EPS

Some Member states without national funding: BG, CY, DK, EL, MT, UK

Some Third states also without EU funding: BR, TN, TW, ... (in proposals also CA, RU)
Private member board

• Prepare the SRA !!!
• Other activities in the 3IA
  • EFECS
  • Brokerage events
  • Other
Governing board

• Work plan !!! (based on SRA)
  • Topics
    • Encouragements
    • Special topics
  • Budgets!!!
  • Eligibility conditions: caps!!
  • Funding rates
  • Evaluation criteria and thresholds
  • Participating states national conditions

• Lighthouses
• Formal decisions (appointing observer for evaluation, staff decisions, budgets, etc....)
• Discussions on strategy
Public authority board

• Evaluation procedures
• Call launch
• Selection of projects
  • Ranking
  • Funding
The office

- Organising the Calls
- Evaluation of the proposals
- the JU Grant agreements
- Monitoring of the projects
- Payments of pre-financing and EU funding
- Impact evaluation
- Communication toward third parties
- Running the boards
- Organisation of events
- Supporting the stakeholders
- Audits
- ...

...
What not?

- CSC (new name CIS?)
  - Legal AND Financial
  - Grant agreement template
  - Audits
  - IT-Tools
  - Procedures (Tools)
  - Helpdesks
    - IT and tools
    - Legal and financial questions
- Financial regulation of the Union
- Issues like Brexit
Research Inquiry Service for legal and finance/cost questions
https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service-and-participant-validation_en,
choosing the subject item "10 – Legal and financial issues" from the drop-down list in the Web form.

IT Helpdesks
Guidance and manuals

Main link on the funding and tender portal
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/manuals

The above main link gives you information on:

• **Reference documents** (select H2020). The most important one is the H2020 Annotated Model Grant Agreement (AMGA – version 5.1)
  

• **Online Manual** (step by step online guide)
  
  http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm

• **IT How to?** (IT support guide)
  
  https://webgate.ec.europa.eu/fpfis/wikis/display/ECResearchGMS/IT+How+To
ECSEL A UNIQUE FUNDING MECHANISM

• EU Funding
  • Commission, H2020 budget
  • 100%/70%? Not in ECSEL
  • Funding rates = Reimbursement rates? Not always in ECSEL!

• National funding
  • Responsibility of the beneficiaries
  • Need for a separate Grant Agreement
  • Use of the cost recognition by the ECSEL Office based on H2020: Israel, Poland, ...
  • ECSEL Office not aware of the national rules!!! We cannot answer your questions on that (sometimes yes...)

• Other funding
  • ESI Funding (IT, RO, LV) > Special rules
  • Regional: DE (Saxony, Thuringen, Bavaria?) , IT, FR, ...
**Project Communication**

CIRCABC

Information on projects for Public Authorities
- Legal documents (Grant Agreement, Amendments,..)
- Reporting (6month, Yearly, ...)
- Other
- Not deliverables
- Consortium corner
- Coordinator is administrator
- Office does the upload of documents
ECSEL: NETWORKS OF PARTNERS AND PROJECTS

- More Moore Technology
- Silicon on Insulator Technology
- MtM IC-Technology
- MtM pilot lines for ISS
- Digitalisation of Industry
- Platforms for Cyber-Physical Systems
- Integrated Smart Systems
- CPS with mixed HW/SW developments
- Other Components

CPS platform developments
Coverage

How does this match with the project portfolio?

⇒ Encouragements:
  • Health,
  • Digital life
  • Safety, Security, Reliability
  • Connectivity

⇒ Special Topics
  Introduced by Lighthouses and GB (working group)
LIGHTHOUSE INITIATIVES

MOBILITY.E
INDUSTRY4.E
HEALTH.E

A container of coordinated activities coming from different programmes using their synergy to achieve overarching common goals.
2014-2018

6 years
10 RIA/IA calls
2 CSA calls
Proposals

Total = 215 proposals!

63 projects selected!
## Participation in proposals

### Entities and Participation

<table>
<thead>
<tr>
<th></th>
<th>Entities</th>
<th>Participation</th>
</tr>
</thead>
<tbody>
<tr>
<td>SME</td>
<td>36%</td>
<td>27%</td>
</tr>
<tr>
<td>LE</td>
<td>39%</td>
<td>36%</td>
</tr>
<tr>
<td>OTHER</td>
<td>24%</td>
<td>37%</td>
</tr>
</tbody>
</table>

### All Participation in Proposals (ALL)

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>ALL YEARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total entities</td>
<td>849</td>
<td>971</td>
<td>841</td>
<td>700</td>
<td>732</td>
<td>2387</td>
</tr>
<tr>
<td>Participations</td>
<td>1393</td>
<td>1564</td>
<td>1332</td>
<td>1092</td>
<td>1089</td>
<td>6470</td>
</tr>
<tr>
<td>Participations/Entity</td>
<td>1.64</td>
<td>1.61</td>
<td>1.58</td>
<td>1.56</td>
<td>1.49</td>
<td>2.71</td>
</tr>
<tr>
<td>%Return</td>
<td>46%</td>
<td>52%</td>
<td>61%</td>
<td>58%</td>
<td>58%</td>
<td>23%</td>
</tr>
<tr>
<td>%New</td>
<td>54%</td>
<td>48%</td>
<td>39%</td>
<td>42%</td>
<td>42%</td>
<td>77%</td>
</tr>
<tr>
<td></td>
<td>Selected projects</td>
<td>Partners</td>
<td>Total H2020 cost in M€</td>
<td>Requested EU funding in M€</td>
<td>Total national cost in M€</td>
<td>Requested national funding in M€</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------------</td>
<td>----------</td>
<td>-------------------------</td>
<td>---------------------------</td>
<td>--------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>RIA 2014-1</td>
<td>6</td>
<td>162</td>
<td>140.7</td>
<td>47.5</td>
<td>140.7</td>
<td>38.0</td>
</tr>
<tr>
<td>IA 2014-2</td>
<td>6</td>
<td>175</td>
<td>463.5</td>
<td>101.8</td>
<td>499.5</td>
<td>90.0</td>
</tr>
<tr>
<td><strong>Total 2014</strong></td>
<td><strong>12</strong></td>
<td><strong>337</strong></td>
<td><strong>604.2</strong></td>
<td><strong>149.2</strong></td>
<td><strong>640.2</strong></td>
<td><strong>128.0</strong></td>
</tr>
<tr>
<td>RIA 2015-1</td>
<td>8</td>
<td>163</td>
<td>168.7</td>
<td>51.7</td>
<td>181.8</td>
<td>391</td>
</tr>
<tr>
<td>IA 2015-2</td>
<td>5</td>
<td>193</td>
<td>421.9</td>
<td>90.6</td>
<td>459.9</td>
<td>87.2</td>
</tr>
<tr>
<td><strong>Total 2015</strong></td>
<td><strong>13</strong></td>
<td><strong>356</strong></td>
<td><strong>590.6</strong></td>
<td><strong>142.2</strong></td>
<td><strong>641.7</strong></td>
<td><strong>126.3</strong></td>
</tr>
<tr>
<td>RIA 2016-1</td>
<td>8</td>
<td>243</td>
<td>214.3</td>
<td>60.5</td>
<td>196.6</td>
<td>478</td>
</tr>
<tr>
<td>IA 2016-2</td>
<td>6</td>
<td>268</td>
<td>503.1</td>
<td>103.0</td>
<td>455.2</td>
<td>85.9</td>
</tr>
<tr>
<td><strong>Total 2016</strong></td>
<td><strong>14</strong></td>
<td><strong>511</strong></td>
<td><strong>719.4</strong></td>
<td><strong>163.5</strong></td>
<td><strong>651.8</strong></td>
<td><strong>133.8</strong></td>
</tr>
<tr>
<td>RIA 2017-2</td>
<td>6</td>
<td>267</td>
<td>215.0</td>
<td>62.6</td>
<td>238.1</td>
<td>53.7</td>
</tr>
<tr>
<td>IA 2017-1</td>
<td>6</td>
<td>182</td>
<td>458.7</td>
<td>109.4</td>
<td>500.0</td>
<td>106.4</td>
</tr>
<tr>
<td><strong>Total 2017</strong></td>
<td><strong>12</strong></td>
<td><strong>449</strong></td>
<td><strong>673.7</strong></td>
<td><strong>171.9</strong></td>
<td><strong>738.1</strong></td>
<td><strong>160.1</strong></td>
</tr>
<tr>
<td>RIA 2018-2</td>
<td>6</td>
<td>205</td>
<td>220.5</td>
<td>64.4</td>
<td>222.1</td>
<td>52.1</td>
</tr>
<tr>
<td>IA 2018-1</td>
<td>6</td>
<td>262</td>
<td>562.3</td>
<td>130.9</td>
<td>598.3</td>
<td>131.5</td>
</tr>
<tr>
<td><strong>Total 2018</strong></td>
<td><strong>12</strong></td>
<td><strong>467</strong></td>
<td><strong>814.1</strong></td>
<td><strong>195.3</strong></td>
<td><strong>820.3</strong></td>
<td><strong>183.6</strong></td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td><strong>63</strong></td>
<td><strong>2120</strong></td>
<td><strong>3370.8</strong></td>
<td><strong>822.2</strong></td>
<td><strong>3492.2</strong></td>
<td><strong>731.7</strong></td>
</tr>
</tbody>
</table>
## National to EU funding Ratio (NER)

### Graph

- Req. National funding / Req. EU funding RIA
- Req. National funding / Req. EU funding IA
- Total Funding/H2020 Cost RIA
- Total Funding/H2020 Cost IA

### Table

<table>
<thead>
<tr>
<th></th>
<th>NER</th>
<th>Overall funding ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIA 2014-1</td>
<td>0.80</td>
<td>61%</td>
</tr>
<tr>
<td>IA 2014-2</td>
<td>0.88</td>
<td>41%</td>
</tr>
<tr>
<td>Total 2014</td>
<td>0.86</td>
<td>46%</td>
</tr>
<tr>
<td>RIA 2015-1</td>
<td>0.76</td>
<td>54%</td>
</tr>
<tr>
<td>IA 2015-2</td>
<td>0.96</td>
<td>42%</td>
</tr>
<tr>
<td>Total 2015</td>
<td>0.89</td>
<td>45%</td>
</tr>
<tr>
<td>RIA 2016-1</td>
<td>0.94</td>
<td>54%</td>
</tr>
<tr>
<td>IA 2016-2</td>
<td>0.85</td>
<td>38%</td>
</tr>
<tr>
<td>Total 2016</td>
<td>0.88</td>
<td>43%</td>
</tr>
<tr>
<td>RIA 2017-2</td>
<td>0.89</td>
<td>55%</td>
</tr>
<tr>
<td>IA 2017-1</td>
<td>1.01</td>
<td>48%</td>
</tr>
<tr>
<td>Total 2017</td>
<td>0.97</td>
<td>50%</td>
</tr>
<tr>
<td>RIA 2018-2</td>
<td>0.84</td>
<td>54%</td>
</tr>
<tr>
<td>IA 2018-1</td>
<td>1.02</td>
<td>47%</td>
</tr>
<tr>
<td>Total 2018</td>
<td>0.96</td>
<td>49%</td>
</tr>
<tr>
<td>Grand Total</td>
<td>0.92</td>
<td>47%</td>
</tr>
</tbody>
</table>
### Results

Licensing can be an alternative to declare if not patentable (e.g., software).

<table>
<thead>
<tr>
<th>Project</th>
<th>Call</th>
<th>Number of Patents</th>
<th>Number of Publications</th>
<th>Number of Prototypes</th>
<th>Number of Clinical Trials</th>
<th>Companies introducing innovation(s) new to the market</th>
<th>How many of these are SMEs</th>
<th>Companies introducing innovation(s) new to the company</th>
<th>How many of these are SMEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>3Car</td>
<td>2014-1</td>
<td>7</td>
<td>70</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EXIST</td>
<td>2014-1</td>
<td>7</td>
<td>22</td>
<td>9</td>
<td>0</td>
<td>11</td>
<td>5</td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td>InForMed</td>
<td>2014-2</td>
<td>4</td>
<td>95</td>
<td>10</td>
<td>6</td>
<td>16</td>
<td>14</td>
<td>9</td>
<td>8</td>
</tr>
<tr>
<td>MANTIS</td>
<td>2014-1</td>
<td>1</td>
<td>55</td>
<td>61</td>
<td>0</td>
<td>20</td>
<td>3</td>
<td>32</td>
<td>13</td>
</tr>
<tr>
<td>OSIRIS</td>
<td>2014-1</td>
<td>0</td>
<td>9</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>PowerBase</td>
<td>2014-2</td>
<td>7</td>
<td>78</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>R2POWER300</td>
<td>2014-2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>RobustSENSE</td>
<td>2014-1</td>
<td>0</td>
<td>9</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>SeNaTe</td>
<td>2014-2</td>
<td>32</td>
<td>56</td>
<td>83</td>
<td>0</td>
<td>31</td>
<td>4</td>
<td>31</td>
<td>4</td>
</tr>
<tr>
<td>SWARMS</td>
<td>2014-1</td>
<td>1</td>
<td>7</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>WAYTOGO FAST</td>
<td>2014-2</td>
<td>7</td>
<td>97</td>
<td>2</td>
<td>0</td>
<td>13</td>
<td>5</td>
<td>13</td>
<td>5</td>
</tr>
<tr>
<td>ADMONT</td>
<td>2014-2</td>
<td>1</td>
<td>6</td>
<td>9</td>
<td>0</td>
<td>12</td>
<td>9</td>
<td>12</td>
<td>9</td>
</tr>
</tbody>
</table>

| ECSEL        | 2014-1 | OSIRIS             | 0                      | 25                    | 9                         | 38                                                 | 7                        | 70                                                     | 7                        |
| ECSEL        | 2014-2 | PowerBase          | 7                      | 80                    | 78                        | 36                                                 | 9                       | 9                                                      | 9                        |
| ECSEL        | 2014-1 | 3Car               | 5                      | 38                    | 70                        | 36                                                 | 9                       | 9                                                      | 9                        |
| ECSEL        | 2014-1 | RobustSENSE        | 0                      | 36                    | 9                         | 20                                                 | 7                       | 7                                                      | 7                        |
| ECSEL        | 2014-2 | InForMed           | 4                      | 12                    | 95                        | 12                                                 | 9                       | 9                                                      | 9                        |

**Extracted from CORDA**

Issues with CORDA
All to be declared!
Could lead to penalties if not.
KPIs

**JU General Objectives**
- Coordinate resources and funding from all sources in order to make a significant contribution to the European Research Area by achieving greater coherence of R&D across Europe
- Achieve higher efficiency by harmonizing procedures and removing uncertainty as to the availability of national budgets and integrating related European activities into the JTs
- Increase overall private and public investment in the two sectors
- Contribute beyond Research & Technology Development to the research and innovation ecosystem - encompassing the participation of SMEs, the enhancement of education and training, and contribution to standards

**ECSEL Specific Objectives**
- Contribute to the development of a strong and globally competitive electronics components and systems industry in the Union
- Ensure the availability of electronic components and systems for key markets and for addressing societal challenges, aiming at keeping Europe at the forefront of technology development, bridging the gap between research and exploitation, strengthening innovation capabilities and creating economic and employment growth in the Union
- Align strategies with Member States to attract private investment and contribute to the effectiveness of public support by avoiding unnecessary duplication and fragmentation of efforts and by maximizing the participation of actors involved in research and innovation
- Maintain and grow a semiconductor and smart system manufacturing capability in Europe, including leadership in manufacturing equipment and processing
- Secure and strengthen a commanding position in design and systems engineering including embedded technologies
- Provide access to all stakeholders to a world-class infrastructure for the design and manufacture of electronic components and embedded cyber-physical and smart systems
- Build a dynamic ecosystem involving Small and Medium-sized Enterprises (SMEs), thereby strengthening existing clusters and fostering the creation of new clusters in promising new areas

**JU Activities**

**Main Output Indicators**
- No. of Participants
- No. of Patents/Innovation Outputs
- Percentage Public/Private Funding
- No. of SMEs
- No. of Projects
- No. of WGs

**Figure 3 ECSEL Intervention Logic Diagram**

Figure 3 shows the...
IMPACT

In future will be checked AFTER the end of project!
Role of beneficiary

41.2 Internal division of roles and responsibilities

The internal roles and responsibilities of the beneficiaries are divided as follows:

(a) Each beneficiary must:

(i) keep information stored in the Participant Portal Beneficiary Register (via the electronic exchange system) up to date (see Article 17);

(ii) inform the coordinator immediately of any events or circumstances likely to affect significantly or delay the implementation of the action (see Article 17);

(iii) submit to the coordinator in good time:

- individual financial statements for itself [and its linked third parties] and, if required, certificates on the financial statements (see Article 20);

- the data needed to draw up the technical reports (see Article 20);

- ethics committee opinions and notifications or authorisations for activities raising ethical issues (see Article 34);

- any other documents or information required by the [Agency or the] Commission under the Agreement, unless the Agreement requires the beneficiary to submit this information directly to the [Agency or the] Commission.
Role of coordinator

41.2 Internal division of roles and responsibilities

(b) The **coordinator** must:

(i) monitor that the action is implemented properly (see Article 7);

(ii) act as the intermediary for all communications between the beneficiaries and the [Commission][Agency] (in particular, providing the [Commission][Agency] with the information described in Article 17), unless the Agreement specifies otherwise;

(iii) request and review any documents or information required by the [Commission][Agency] and verify their completeness and correctness before passing them on to the [Commission][Agency];

(iv) submit the deliverables and reports to the [Commission][Agency] (see Articles 19 and 20);

(v) ensure that all payments are made to the other beneficiaries without unjustified delay (see Article 21);

(vi) inform the [Commission][Agency] of the amounts paid to each beneficiary, when required under the Agreement (see Articles 44 and 50) or requested by the [Commission][Agency].

The coordinator may not delegate or subcontract the above-mentioned tasks to any other beneficiary or third party (including linked third parties).
If not...

Consequences of non-compliance

If a beneficiary breaches any of its obligations under this Article, the grant may be reduced (see Article 43). Such a breach may also lead to any of the other measures described in Chapter 6.
Sanctions

ARTICLE 43 — REDUCTION OF THE GRANT

43.1 Conditions

The [Commission][Agency] may — after termination of the participation of a beneficiary, at the payment of the balance or afterwards — reduce the grant amount (see Article 5.1), if:

(a) a beneficiary (or a natural person who has the power to represent or take decisions on its behalf) has committed:

(i) substantial errors, irregularities or fraud or

(ii) serious breach of obligations under the Agreement or during the award procedure (including improper implementation of the action, submission of false information, failure to provide required information, breach of ethical principles) or

(a) a beneficiary (or a natural person who has the power to represent or take decision on its behalf) has committed — in other EU or Euratom grants awarded to it under similar conditions — systemic or recurrent errors, irregularities, fraud or serious breach of obligations that have a material impact on this grant (extension of findings from other grants to this grant; see Article 22.5.2).
QUESTIONS?